EDITORIAL

Could stress ulcer prophylaxis increase mortality in high-acuity patients?

Michael O. Harhay^{1,2*}, Paul J. Young^{3,4} and Manu Shankar-Hari^{5,6}

© 2020 Springer-Verlag GmbH Germany, part of Springer Nature

Clinically important upper gastrointestinal (GI) bleeding occurs in 1.6–3.6% of critically ill adults [1]. This complication is associated with prolonged intensive care unit (ICU) and hospital lengths of stay, and high mortality [1]. To reduce the risk of upper GI bleeding, nearly 75% of critically ill patients are given stress ulcer prophylaxis [1]. However, because clinically important upper GI bleeding is very uncommon in some patient groups, there remains uncertainty about the ubiquity of benefit from prophylaxis. Moreover, although the risks of nosocomial pneumonia [2–4] and *Clostridioides difficile* infection [2] associated with exposure to proton pump inhibitors (PPIs) in observational studies have not been confirmed in RCTs [5], the potential for harm in some patient groups still exists. Overall, it remains highly plausible that the balance of risks and benefits for stress ulcer prophylaxis differs depending on the patient's circumstances.

This background information highlights the importance of considering not only average treatment effects, but also whether there is heterogeneity of treatment effect (HTE), when evaluating data on the safety and efficacy of stress ulcer prophylaxis. The average treatment effect of an intervention is the difference in outcomes between the intervention and comparator groups when comparing all patients. HTE is when the treatment effect varies by one or more baseline characteristics in what appears to be a non-random fashion [6]. In the Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) trial [7], the largest placebo-controlled randomized clinical trial of stress ulcer prophylaxis in critically ill patients,

there was no statistically significant mortality difference between the PPI and placebo groups, but patients randomized to receive PPIs had less clinically important upper GI bleeding. While these data suggest that PPIs are effective at preventing clinically important upper GI bleeding, how clinicians should act on them is complicated when one considers the possibility of HTE.

In relation to 90-day mortality, which was the primary outcome in the SUP-ICU trial [7], there was evidence of HTE in a pre-planned analysis evaluating the impact of baseline illness severity on the mortality treatment effect. Illness severity was determined using the Simplified Acute Physiology Score II (SAPS-II), which is a multivariable mortality risk score. The primary study findings raised concerns about the use of PPI prophylaxis for the sickest critically ill patients because such patients appeared to have a possible increase in mortality when randomized to receive PPIs (relative risk and 95% confidence interval (CI) for PPI vs. placebo, 1.13 (0.99–1.30) in those with a SAPS-II > 53 points vs. 0.92 (0.78–1.09) in those with a SAPS-II ≤ 53 points; $P=0.05$ for interaction). Unfortunately, while HTE is intuitive clinically, it is notoriously difficult to identify empirically. A central problem is that trials are almost universally designed with sample sizes that are only sufficient to assess differences in average treatment effects. Thus, analyses among subgroups, even pre-planned ones, can lead to false-negative findings from inadequate power and false-positives from multiple testing [8–11]. Small sample sizes in subgroups also introduce imprecision in treatment effect estimates. In addition, subgroup analyses typically focus on a single characteristic that is similar within strata, when many other characteristics vary and may influence the observed HTE.

Because of these concerns, the signal towards harm in patients with high illness severity as measured by SAPS-II has motivated additional analyses. The SUP-ICU

*Correspondence: mharhay@pennmedicine.upenn.edu

¹ Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, 304 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021, USA
Full author information is available at the end of the article

investigators have previously demonstrated that the observed HTE did not appear to be due to chance baseline imbalances between groups in high-acuity patients [12]. In this issue of *Intensive Care Medicine* [13], Granholm and colleagues provide a major methodological extension to their prior analysis [12] by incorporating Bayesian priors into the HTE analyses using Bayesian hierarchical logistic regression models [13]. The current approach [13] offers two substantial strengths. First, compared to the previous analysis [12], it further reduces the risk of type 1 errors. Second, it permits the concurrent assessment of the existence of HTE using several “prior” distributions. These prior distributions provide an empirical approach of impacting the effect estimate by formally weighting the analysis with assumptions regarding potential effect distributions [14]. The authors included a weakly informative prior centered on effect sizes informed by previous RCTs, but wide enough to encompass all plausible effect sizes, as well as a pessimistic prior favoring the placebo arm. By evaluating all these prior distributions, the authors were able to examine the robustness of the empirical result suggesting higher mortality among sicker patients (i.e., HTE). All of the analyses conducted suggested a small, but harmful impact of PPIs in patients with high illness acuity [13]. This included effects not just on 90-day mortality, but also on infectious adverse events. Importantly, HTE was observed both among patients with high illness severity (as measured by SAPS-II) and also in those with more risk factors for clinically important upper GI bleeding [13].

The results of the analysis by Granholm and colleagues [13] are particularly compelling when viewed together with the recently published Proton Pump Inhibitors versus Histamine-2 Receptor Blockers for Ulcer Prophylaxis Therapy in the Intensive Care Unit (PEPTIC) study [15]. The PEPTIC trial was a randomized, open-label, cluster-crossover trial that compared PPIs and histamine 2 receptor blockers (H₂RBs) for stress ulcer prophylaxis in 26,982 mechanically ventilated adults. In the PEPTIC trial [15], similar to the SUP-ICU trial [7], patients with high illness severity who were assigned to PPIs had higher mortality than comparator patients.

Based on the available evidence, we surmise that, although considerable uncertainty remains, the inferences from SUP-ICU and PEPTIC are consistent with the hypothesis that PPIs increase the risk of death in patients with higher illness severity. While, the overall evidence that PPIs reduce upper GI bleeding in the critically ill is unequivocal [5, 15], it appears that most upper GI bleeds are not fatal, and the attributable mortality from such bleeds appears to be low [16]. Therefore, we suspect that most patients would exchange the small increased risk of upper GI bleeding to avoid a therapy that might increase

their risk of death, despite the uncertainty. These data are not definitive and further research is warranted, but for now, they are likely to be sufficient to prompt a shift by many clinicians away from the routine use of PPIs for stress ulcer prophylaxis in patients with high illness severity.

Author details

¹ Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, 304 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021, USA. ² Palliative and Advanced Illness Research (PAIR) Center and Pulmonary and Critical Care Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ³ Medical Research Institute of New Zealand, Wellington, New Zealand. ⁴ Intensive Care Unit, Wellington Hospital, Wellington, New Zealand. ⁵ Guy's and St. Thomas' NHS Foundation Trust, ICU Support Offices, St. Thomas' Hospital, London, UK. ⁶ School of Immunology and Microbial Sciences, Kings College London, London, UK.

Author contributions

All authors developed the outline. Dr. Harhay wrote the first draft. All authors contributed to the critical revision of the manuscript for important intellectual content.

Funding

Dr. Harhay is supported by the United States National Institutes of Health, National Heart, Lung, and Blood Institute (R00 HL141678). Dr. Shankar-Hari is supported by the National Institute for Health Research Clinician Scientist Award (CS-2016-16-011). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. This research was conducted during the tenure of a Health Research Council of New Zealand Clinical Practitioner Research Practitioner Fellowship held by Dr. Young.

Compliance with ethical standards

Conflicts of interest

MS-H is on the Editorial Board for ICM and declares no other competing interests. PY is the Chief Investigator for the PEPTIC trial and declares this as an academic conflict of interest.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 31 January 2020 Accepted: 4 February 2020

Published online: 19 February 2020

References

1. Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, McArthur C, Cook D, Nielsen N, Pelosi P, Keus F, Guttormsen AB, Moller AD, Moller MH, SUP-ICU co-authors (2015) Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. *Intensive Care Med* 41(5):833–845. <https://doi.org/10.1007/s00134-015-3725-1>
2. Maclaren R, Reynolds PM, Allen RR (2014) Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. *JAMA Intern Med* 174(4):564–574. <https://doi.org/10.1001/jamainternmed.2013.14673>
3. Miano TA, Reichert MG, Houle TT, MacGregor DA, Kincaid EH, Bowton DL (2009) Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. *Chest* 136(2):440–447. <https://doi.org/10.1378/chest.08-1634>

4. Bateman BT, Bykov K, Choudhry NK, Schneeweiss S, Gagne JJ, Polinski JM, Franklin JM, Doherty M, Fischer MA, Rassen JA (2013) Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. *BMJ* 347:f5416. <https://doi.org/10.1136/bmj.f5416>
5. Wang Y, Ye Z, Ge L, Siemieniuk RAC, Wang X, Wang Y, Hou L, Ma Z, Agoritsas T, Vandvik PO, Perner A, Moller MH, Guyatt GH, Liu L (2020) Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis. *BMJ* 368:l6744. <https://doi.org/10.1136/bmj.l6744>
6. Dahabreh IJ, Hayward R, Kent DM (2016) Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence. *Int J Epidemiol* 45(6):2184–2193. <https://doi.org/10.1093/ije/dyw125>
7. Krag M, Marker S, Perner A, Wetterslev J, Wise MP, Schefold JC, Keus F, Guttormsen AB, Bendel S, Borthwick M, Lange T, Rasmussen BS, Siegemund M, Bundgaard H, Elkmann T, Jensen JV, Nielsen RD, Liboriussen L, Bestle MH, Elkjaer JM, Palmqvist DF, Backlund M, Laake JH, Badstolokken PM, Gronlund J, Breum O, Walli A, Winding R, Iversen S, Jarnvig IL, White JO, Brand B, Madsen MB, Quist L, Thornberg KJ, Moller A, Wiis J, Granholm A, Anthon CT, Meyhoff TS, Hjortrup PB, Aagaard SR, Andreassen JB, Sorensen CA, Haure P, Hauge J, Hollinger A, Scheuzger J, Tuchscherer D, Vuillomenet T, Takala J, Jakob SM, Vang ML, Paelestik KB, Andersen KLD, van der Horst ICC, Dieperink W, Fjolner J, Kjer CKW, Solling C, Solling CG, Karttunen J, Morgan MPG, Sjobo B, Engstrom J, Agerholm-Larsen B, Moller MH, SUP-ICU Trial Group (2018) Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU. *N Engl J Med* 379(23):2199–2208. <https://doi.org/10.1056/NEJMoa1714919>
8. Kent DM, Steyerberg E, van Klaveren D (2018) Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. *BMJ* 363:k4245. <https://doi.org/10.1136/bmj.k4245>
9. Burke JF, Sussman JB, Kent DM, Hayward RA (2015) Three simple rules to ensure reasonably credible subgroup analyses. *BMJ* 351:h5651. <https://doi.org/10.1136/bmj.h5651>
10. Brookes ST, Whitley E, Egger M, Smith GD, Mulheran PA, Peters TJ (2004) Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. *J Clin Epidemiol* 57(3):229–236. <https://doi.org/10.1016/j.jclinepi.2003.08.009>
11. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G (2001) Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. *Health Technol Assess* 5(33):1–56. <https://doi.org/10.3310/hta5330>
12. Marker S, Perner A, Wetterslev J, Krag M, Lange T, Wise MP, Borthwick M, Bendel S, Keus F, Guttormsen AB, Schefold JC, Moller MH, SUP-ICU Investigators (2019) Pantoprazole prophylaxis in ICU patients with high severity of disease: a post hoc analysis of the placebo-controlled SUP-ICU trial. *Intensive Care Med* 45(5):609–618. <https://doi.org/10.1007/s00134-019-05589-y>
13. Granholm A, Marker S, Krag M, Zampieri FG, Thorsen-Meyer HC, Kaas-Hansen BS, van der Horst ICC, Lange T, Wetterslev J, Perner A, Moller MH (2020) Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial. *Intensive Care Med*. <https://doi.org/10.1007/s00134-019-05903-8>
14. Wijesundera DN, Austin PC, Hux JE, Beattie WS, Laupacis A (2009) Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. *J Clin Epidemiol* 62(1):13–21. <https://doi.org/10.1016/j.jclinepi.2008.07.006>
15. The PEPTIC Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group, Alberta Health Services Critical Care Strategic Clinical Network, and the Irish Critical Care Trials Group, Young PJ, Bagshaw SM, Forbes AB, Nichol AD, Wright SE, Bailey M, Bellomo R, Beasley R, Brickell K, Eastwood GM, Gattas DJ, van Haren F, Litton E, Mackle DM, McArthur CJ, McGuinness SP, Mouncey PR, Navarra L, Opgenorth D, Pilcher D, Saxena MK, Webb SA, Wiley D, Rowan KM (2020) Effect of stress ulcer prophylaxis with proton pump inhibitors vs histamine-2 receptor blockers on in-hospital mortality among ICU patients receiving invasive mechanical ventilation: the PEPTIC randomized clinical trial. *JAMA*. <https://doi.org/10.1001/jama.2019.22190>
16. Cook DJ, Griffith LE, Walter SD, Guyatt GH, Meade MO, Heyland DK, Kirby A, Tryba M (2001) The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. *Crit Care* 5(6):368–375. <https://doi.org/10.1186/cc1071>